Navigation Links
Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
Date:4/11/2013

SUNNYVALE, Calif., April 11, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the Phase III clinical trial (RESONATE™-2), a monotherapy trial using ibrutinib versus chlorambucil in elderly patients with newly diagnosed chronic lymphocytic leukemia / small lymphocyctic lymphoma (CLL/SLL) has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a fourth $50 million milestone payment obligation from Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, worldwide collaborator on ibrutinib in oncology.

This trial is a randomized, multicenter, open-label Phase III study of ibrutinib (PCI-32765) as a monotherapy versus chlorambucil in patients 65 years or older with treatment-naïve CLL/SLL. The study design is in accord with a Special Protocol Assessment (SPA). The study is designed to demonstrate superiority of ibrutinib with the primary endpoint of progression-free survival (PFS); the comparator is single agent chlorambucil. This global study is planned to enroll 272 patients worldwide.

Further information about this trial can be found at www.clinicaltrials.gov:
NCT01722487 – "A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)."

About the Janssen Collaboration
As previously announced on December 8, 2011, Pharmacyclics entered into a worldwide collaboration with Janssen to develop and commercialize ibrutinib, a novel, oral, first-in-class Bruton's Tyrosine Kinase (BTK) inhibitor. Pharmacyclics received from Janssen an upfront payment totaling $150 million upon signing the contr
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
2. Pharmacyclics, Inc. Prices Public Offering of Common Stock
3. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
4. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
5. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
6. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
7. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
8. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
9. New survey finds women who suffer from migraines want a better understanding of migraine triggers
10. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
11. Cardinal Health Foundation, The Ohio State University Launch Fourth Toolkit to Help Reduce Abuse of Prescription Drugs on College Campuses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 The Chinese wound care market ... rise in the incidence of lifestyle diseases, coupled with ... affordability of better quality of wound care products provide ... coverage of public health insurance schemes and increased reimbursement ... Based on the findings of primary and secondary researches, ...
(Date:9/30/2014)... , N.J. and NEW BRUNSWICK, N.J., Sept. 30, 2014 /PRNewswire-USNewswire/ ... that allows Kessler Foundation and New Jersey Health ... research, education and patient care programs has been ... chief executive officer of Kessler Foundation and ... Health Foundation. "The experience of New ...
(Date:9/30/2014)... 2014 BioStructures, LLC has been awarded ... Tissue Banks (AATB), it was announced today by ... Accreditation follows an intensive nine-month process, including ... inspector.  It establishes that the level of medical, ... or exceeds the standards set by the AATB.  ...
Breaking Medicine Technology:China Wound Care Market 2China Wound Care Market 3Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Biostructures, LLC Earns AATB Accreditation 2
... 13 Rcadia Medical Imaging today announced that ... of coronary CT angiography (cCTA) will be featured in ... scientific meeting of the Society of Cardiovascular Computed Tomography ... .  SCCT is the international professional society representing physicians, ...
... FOREST, Ill. , July 13 ... leading provider of clinical information and medication delivery technologies, ... clinical surveillance system helped clinicians at Memorial ... an increase in infection-control interventions. The hospital, which used ...
Cached Medicine Technology:Rcadia Announces Five COR Analyzer® Studies to be Presented at SCCT Annual Scientific Meeting 2Rcadia Announces Five COR Analyzer® Studies to be Presented at SCCT Annual Scientific Meeting 3Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections 2Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections 3Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections 4Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections 5Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections 6
(Date:9/30/2014)... 2014 Integrated Medicine Alliance , ... another new medical specialty practice through a unique partnership ... will be located within the company’s Shrewsbury location and ... Isaac Tawfik of American Heart Center, P.C., a highly ... will offer Integrated Medicine Alliance patients top notch cardiovascular ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Glycodrive ... Star Nutraceuticals designed to help maximize lean, strong muscle ... the body’s absorption of glucose has caught the attention ... “The main purpose behind Glycodrive is to help the ... muscle,” reports Michaels. “Carbs are essential in the muscle-building ...
(Date:9/30/2014)... September 30, 2014 VisitandCare.com ... Turkey has gone up more than 79 percent in ... tourism company also reported total revenue tripled for its ... The company’s professional strategy has allowed them to partner ... designed for patient comfort and privacy — with state-of-the-art ...
(Date:9/30/2014)... Washington, DC (PRWEB) September 30, 2014 A ... the world to combat an epidemic that, left unchecked, could ... no, they are not headed to Africa. John Rogers, the ... headed to North Korea to fight a disease most think ... the US some 80 years ago is on the comeback ...
(Date:9/30/2014)... Levothyroxine is considered the gold standard therapy for ... of therapies for the condition including combining levothyroxine ... say a team of investigators.,1Their analysis, published as a ... finds insufficient consistent data exist to recommend a change ... under various trade names, such as Synthroid as ...
Breaking Medicine News(10 mins):Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2
... March 27 /PRNewswire/-- CVCTA Education, the leader in,physician ... new education,program that helps physicians reduce the radiation ... properly performed, radiation doses during CTA,are in the ... has been attributed,to creating a health risk. However, ...
... The following statement was,issued today by the law firm ... hereby given that a class action lawsuit was filed in ... behalf,of all purchasers of securities of NeuroMetrix Inc. (Nasdaq: ... March 6,2007, inclusive (the "Class Period")., If you wish ...
... the 37th Annual Meeting of the American Association for ... Hotel in Dallas, several eminent scientists will be part ... and Friday mornings, the meeting will feature a Distinguished ... All lectures will occur in the Stemmons Ballroom at ...
... Following is a summary of the keynote presentations, symposia, ... of the American Association for Dental Research, convening April ... Presentations , Wednesday, April 2 , ... from the Analysis of Clinical Failures,Susanne Scherrer (University of ...
... however most believed,they were not pregnant at the ... with each case., HARRISBURG, Pa., March 27 ... 90 cases reported to the,Pennsylvania Patient Safety Authority ... were not pregnant, according to analysis published in ...
... Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today that ... Drugs: The Future of Molecular Diagnostics Roundtable,Conference" in New ... Eastern,Time. The presentation is scheduled to be webcast live ... information section of Gen-Probe,s website,at http://www.gen-probe.com . The ...
Cached Medicine News:Health News:CVCTA Education Announces New LOW DOSE Initiative for CT Angiograms 2Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 4Health News:Eminent scientists to lecture in Dallas 2Health News:Eminent scientists to lecture in Dallas 3Health News:Keynoters, symposia, workshops highlight dental research meeting 2Health News:Keynoters, symposia, workshops highlight dental research meeting 3Health News:Keynoters, symposia, workshops highlight dental research meeting 4Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 2Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 3Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 4Health News:Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference 2
Curved left, Hardy Curettes, bayonet, working distance 120 mm, total length 241 mm....
Toothed pituitary rongeur. Straight....
Micro cup pituitary forceps, semi-malleable shafts....
Teardrop dissector. 90, 5 mm....
Medicine Products: